This product has not been evaluated by SAHPRA. For information purposes only — not intended to diagnose, treat, cure or prevent any disease.
Mind & MoodResearch vialnootropicfocusbdnfstroke-recoveryresearch
Semax
ACTH(4-10) analogue for cognition and BDNF
R 585
30mg vial
Raises hippocampal BDNFDolotov 2006: a single 50 µg/kg intranasal dose in rats produced a 1.4-fold rise in BDNF protein, 3-fold rise in BDNF mRNA, and increased trkB phosphorylation.
Stroke-recovery signalRussian clinical work in ischaemic stroke reports faster Barthel-index recovery and elevated plasma BDNF on intranasal 6,000 µg/day across two 10-day courses.
Attention and short-term memoryHealthy-volunteer studies report improvements in attention and short-term memory after intranasal dosing.
Intranasal deliveryConvenient nasal-spray administration avoids injection.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analogue of ACTH(4-10) developed in the 1980s at the Institute of Molecular Genetics in Moscow. It is on the Russian Federation's List of Vital and Essential Drugs and is prescribed there for stroke recovery and cognitive complaints. Outside Russia it remains unapproved and largely unstudied in Western trials.
More in Mind & Mood
You might also like
Mind & MoodR 715
5mg vial
DSIP
Delta sleep-inducing peptide — a nonapeptide isolated in 1977 from the cerebral venous blood of rabbits in induced slow-wave sleep. Crosses the blood-brain barrier; receptor target has never been definitively identified.
View details →
Mind & MoodR 585
30mg vial
Selank
Synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Moscow as a stabilised analogue of the immunomodulatory peptide tuftsin. Registered as an anxiolytic in Russia.
View details →
Regulatory
This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA).
For information purposes only — not intended to diagnose, treat, cure or prevent any disease.